Blood Lipid Levels, Lipid Lowering Medications, and the Incidence of Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study

Letter by Watanabe and Aizawa regarding article, "Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) Study".

Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: the atherosclerosis risk in communities study.

BACKGROUND Several cardiovascular risk factors have been associated with the risk of atrial fibrillation (AF). Limited and inconsistent evidence exists on the association of blood lipid levels and lipid-lowering medication use with AF risk. METHODS AND RESULTS We analyzed 13 969 participants (25% African American, 45% men) free of AF at baseline from the Atherosclerosis Risk in Communities st...

Lipid-lowering pharmacotherapy and socioeconomic status: atherosclerosis risk in communities (ARIC) surveillance study

BACKGROUND Lipid-reduction pharmacotherapy is often employed to reduce morbidity and mortality risk for patients with dyslipidemia or established cardiovascular disease. Associations between socioeconomic factors and the prescribing and use of lipid-lowering agents have been reported in several developed countries. METHODS We evaluated the association of census tract-level neighborhood househ...

Study of steroidal compounds from peel and seed of some pomegranate cultivars (Punica granatum L.) and investigating the effect of pomegranate seed oil on blood lipid levels in hypercholesterolemic rabbits

Background: High level of blood cholesterol can cause diseases such as atherosclerosis, high blood pressure, cardiovascular diseases, and increase the chance of apoplexy and fatty liver. Unsaturated fatty acids play important roles in preventing cardiovascular diseases because they decrease total cholesterols and LDL-C in the blood. Objective: The study investigates some sterol compounds of Ira...

Despite Affordability, Low Utilization of Lipid Lowering Drugs in Iran: Trend Analysis and Benchmarking 2005-2016

Dyslipidemia is responsible for great mortality and morbidity each year. Little data are available on the availability and affordability of Dyslipidemia medications in low and middle incomes countries. In a retrospective time-series study, we examined the utilization pattern and affordability of lipid-lowering medications in Iran as a lower middle-income country. We initially calculated the def...